Pantoprazol Elac (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Elac, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and ulcers in adults.

GNH USA supplies Pantoprazol Elac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Elac is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates healing of erosive lesions in the oesophagus. - Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare endocrine disorder.

Pantoprazol Elac may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhoea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: signs of hepatic stress. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing Pantoprazol Elac, clinicians should consider several safety aspects: - Renal impairment: adjust monitoring if patient has reduced kidney function. - Hepatic impairment: use with caution in patients with liver disease. - Long‑term therapy: evaluate need for periodic assessment of bone density and magnesium levels. - Drug interactions: review concomitant medications for potential CYP‑related effects. - Pregnancy and lactation: limit use to situations where benefit outweighs potential risk. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Elac can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): decreased efficacy. - Clopidogrel: diminished antiplatelet activity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR values. - Methotrexate: reduced renal clearance may raise serum levels. - Digoxin: slight increase in serum concentration. - Oral contraceptives: potential decrease in hormonal efficacy.